A Review on Venous Thrombosis: Management with anticoagulants
Abstract
Thrombosis is the most common condition and the world's leading cause of death due to blood clot development in blood arteries. Thromboembolism includes classification based on where the thrombus gets attached to the blood vessels. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are two of the main causes of vascular death globally, making up venous thromboembolism (VTE). According to estimates, the yearly incidence rates of VTE in individuals with European ancestry vary from 104 to 183 per 100,000 person-years. Thrombus development and propagation are dependent upon the existence of anomalies in blood flow, blood vessel wall, and blood clotting components, which are together referred to as Virchow's triad. A comprehensive diagnostic approach, which includes clinical evaluation, D-dimer testing, ultrasonography, and lung scan, provided a non-invasive diagnosis for most outpatients with suspected venous thromboembolism. Anticoagulant medication is the primary and established treatment for people who have acute venous thromboembolism (VTE). Among the treatment options available, UFH & LMWH are found to be safe for the growing fetus as they appear to not cross the placenta. Oral anticoagulants targeting thrombin or factor Xa have been introduced, replacing vitamin K antagonists. In a study involving DOACs vs VKAs in patients with pre-existing heart conditions, patients receiving DOACs for non-valvular atrial fibrillation had predominantly superior efficacy and safety.
Keywords: Venous thromboembolism, Anticoagulants, Deep vein thrombosis, Pulmonary embolism, Thrombus
Keywords:
Venous thromboembolism, Anticoagulants, Deep vein thrombosis, Pulmonary embolism, ThrombusDOI
https://doi.org/10.22270/jddt.v14i10.6772References
World Health Organization; 2023. Available at https://www.who.int/news-room/factsheets/detail/noncommunicable-diseases. Accessed September 16, 2023.
Fang J, Alderman MH. Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med. 2002;113(2):208-214. https://doi.org/10.1016/S0002-9343(02)01172-5
Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43-53. https://doi.org/10.1016/S1474-4422(03)00266-7
• White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(suppl 1) -I-8. https://doi.org/10.1161/01.CIR.0000078468.11849.66
Mackman, N, Bergmeier, W, Stouffer GA, Weitz, J.I. Therapeutic strategies for thrombosis: New targets and approaches. Nat. Rev. Drug Discov. 2020; 19(5), 333-352. https://doi.org/10.1038/s41573-020-0061-0
Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ. Res. 2016; 118:1340-1347. https://doi.org/10.1161/CIRCRESAHA.115.306841
Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism: The Worcester DVT Study. Arch. Intern. Med. 1991;151:933-938. https://doi.org/10.1001/archinte.1991.00400050081016
Oger E. Incidence of venous thromboembolism: A community-based study in western France. Thromb Haemost. 2000;83(5):657-660. doi: 10.1055/s-0037-1613887. https://doi.org/10.1055/s-0037-1613887
Riva N. Cerebral and splanchnic vein thrombosis: Advances, challenges, and unanswered questions. J Clin Med. 2020;9(3):743. doi: 10.3390/jcm9030743. https://doi.org/10.3390/jcm9030743
Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(suppl 1)-I30. https://doi.org/10.1161/01.CIR.0000078464.82671.78
Ho WK. Deep vein thrombosis risks and diagnosis. Aust Fam Physician. 2010;39(7):468-474.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(suppl 1)-I8. https://doi.org/10.1161/01.CIR.0000078468.11849.66
Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ. 2006;175(9):1087-1092. https://doi.org/10.1503/cmaj.060366
Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146(3):204-210. https://doi.org/10.7326/0003-4819-146-3-200702060-00149
Kahn SR. The post-thrombotic syndrome. Thromb Res. 2011;127(suppl 3)-S92. https://doi.org/10.1016/S0049-3848(11)70024-X
Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363(3):210-274. https://doi.org/10.1056/NEJMra0907731
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(suppl 1)-I8. https://doi.org/10.1161/01.CIR.0000078468.11849.66
McRae S. Pulmonary embolism. Aust Fam Physician. 2011;39(6):462-466.
Heit JA. Venous thromboembolism: Disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617. https://doi.org/10.1111/j.1538-7836.2005.01415.x
Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960;275(7138):1309-1312. https://doi.org/10.1016/S0140-6736(60)92299-6
Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279(6):458-462. https://doi.org/10.1001/jama.279.6.458
Barczyk A, Pierzchała W. Risk factors of venous thromboembolism. Wiad Lek. 2001;54(5-6):311-324. PMID: 11556214.
Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938. https://doi.org/10.1001/archinte.1991.00400050081016
Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363(9425):1925-1933. https://doi.org/10.1016/S0140-6736(04)16405-2
Zakai NA, McClure LA, Judd SE, et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;129(14):1502-1509. https://doi.org/10.1161/CIRCULATIONAHA.113.006472
Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg. 2004;91(3):424-428. https://doi.org/10.1002/bjs.4454
Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol. 2000;85(11):1334-1337. https://doi.org/10.1016/S0002-9149(00)00766-9
Hooper WC, Holman RC, Heit JA, Cobb N. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res. 2002;108(5):273-278. https://doi.org/10.1016/S0049-3848(03)00058-6
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. doi: 10.1038/nrcardio.2015.83. Epub 2015 Jun 16. PMID: 26076949; PMCID: PMC4624298. https://doi.org/10.1038/nrcardio.2015.83
Mackay JA, Lyman DT, Alizadeh H, et al. Venous thromboembolism: Risk assessment, prevention, and treatment. Am J Med. 2015;128(6):689.e1-689.e22. doi: 10.1016/j.amjmed.2015.06.039. https://doi.org/10.1016/j.amjmed.2015.06.039
Ashorobi D, Ameer MA, Fernandez R. Thrombosis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538430/.
Turpie AGG. ABC of antithrombotic therapy: Venous thromboembolism: Pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887-890. https://doi.org/10.1136/bmj.325.7369.887
Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301(16):855-858. https://doi.org/10.1056/NEJM197910183011602
Lagerstedt C, Fagher B, Olsson CG, Öqvist B, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;326(8454):515-518. https://doi.org/10.1016/S0140-6736(85)90459-3
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506-1511. https://doi.org/10.1056/NEJM199705223362107
Hirsh J. Heparin. N Engl J Med. 1991;324(22):1565-1574. https://doi.org/10.1056/NEJM199105303242206
Ortel TL, Neumann I, Ageno W, Beyth RJ, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, Flórez ID, Izcovich A, Nieuwlaat R, Ross S, Schünemann HJ, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(22):5778-5811. https://doi.org/10.1182/bloodadvances.2020001830
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452-467. https://doi.org/10.1016/j.annonc.2022.12.014
Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood. 2005;106(2):401-407. https://doi.org/10.1182/blood-2005-02-0626
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018 Jul;132(1):e1-e17. https://doi.org/10.1097/AOG.0000000000002706
Coordinating Committee, De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012;59(16):1413-1425. https://doi.org/10.1016/j.jacc.2012.02.008
Nakamura M, Okano Y, Minamiguchi H, Munemasa M, Sonoda M, Yamada N, Hanzawa K, Aoyagi N, Tsujimoto H, Sarai N, Nakajima H, Kunieda T. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J. 2011;75(6):1424-32. https://doi.org/10.1253/circj.CJ-10-1036
Nakamura M, Yamada N, Ito M. Novel anticoagulant therapy of venous thromboembolism: Current status and future directions. Ann Vasc Dis. 2017;10(2):92-98. https://doi.org/10.3400/avd.ra.17-00015
Büller HR, Décousus H, Grosso MA, et al.; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(14):1406-1415. https://doi.org/10.1056/NEJMoa1306638
Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. https://doi.org/10.1056/NEJMoa1302507
Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA, et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS ONE. 2018;13(5) https://doi.org/10.1371/journal.pone.0197583
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. https://doi.org/10.1056/NEJMoa1009638
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. https://doi.org/10.1056/NEJMoa1302507
Guan Z, Wang R, Hussain RH, Fredenburgh JC, Jaffer IH, Weitz JI. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. J Thromb Haemost. 2023;21(1):76-82. https://doi.org/10.1016/j.jtha.2022.10.020
Weitz JI, Eikelboom JW. What is the future of factor XI inhibitors? Circulation. 2022;146(25):1899-1902. https://doi.org/10.1161/CIRCULATIONAHA.122.061132
Published
Abstract Display: 357 
PDF Downloads: 321 PDF Downloads: 122 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.